MA71727A - Dérivés bicycliques de tétrahydrothiazépine - Google Patents

Dérivés bicycliques de tétrahydrothiazépine

Info

Publication number
MA71727A
MA71727A MA71727A MA71727A MA71727A MA 71727 A MA71727 A MA 71727A MA 71727 A MA71727 A MA 71727A MA 71727 A MA71727 A MA 71727A MA 71727 A MA71727 A MA 71727A
Authority
MA
Morocco
Prior art keywords
tetrahydrothiazepine
bicyclic
derivatives
tetrahydrothiazepine derivatives
bicyclic tetrahydrothiazepine
Prior art date
Application number
MA71727A
Other languages
English (en)
Inventor
Thomas Luebbers
Holger Kuehne
Roman HUTTER
Laetitia Janine MARTIN
Barbara Johanna MUELLER
Marco BRANDSTAETTER
Maria Emilia Di Francesco
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of MA71727A publication Critical patent/MA71727A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA71727A 2022-08-11 2023-08-09 Dérivés bicycliques de tétrahydrothiazépine MA71727A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22189817 2022-08-11
PCT/EP2023/071988 WO2024033388A1 (fr) 2022-08-11 2023-08-09 Dérivés bicycliques de tétrahydrothiazépine
EP23754298.0A EP4568958A1 (fr) 2022-08-11 2023-08-09 Dérivés bicycliques de tétrahydrothiazépine

Publications (1)

Publication Number Publication Date
MA71727A true MA71727A (fr) 2025-05-30

Family

ID=82898783

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71727A MA71727A (fr) 2022-08-11 2023-08-09 Dérivés bicycliques de tétrahydrothiazépine

Country Status (17)

Country Link
US (1) US20260035364A1 (fr)
EP (1) EP4568958A1 (fr)
JP (1) JP2025526727A (fr)
KR (1) KR20250038674A (fr)
CN (1) CN119698413A (fr)
AR (1) AR130194A1 (fr)
AU (1) AU2023322637A1 (fr)
CL (1) CL2025000379A1 (fr)
CO (1) CO2025001103A2 (fr)
CR (1) CR20250042A (fr)
IL (1) IL318163A (fr)
MA (1) MA71727A (fr)
MX (1) MX2025000918A (fr)
PE (1) PE20251399A1 (fr)
TW (1) TW202417438A (fr)
WO (1) WO2024033388A1 (fr)
ZA (1) ZA202408363B (fr)

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
KR100441557B1 (ko) 1994-07-21 2005-08-05 아크조 노벨 엔.브이. 고리형케톤과산화물조성물
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222231A1 (fr) 1995-06-07 1996-12-19 Imclone Systems Incorporated Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
CN1160338C (zh) 1998-11-19 2004-08-04 沃尼尔·朗伯公司 N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
CA2663057C (fr) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles en tant que modulateurs d'indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (fr) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (fr) 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
WO2009073620A2 (fr) 2007-11-30 2009-06-11 Newlink Genetics Inhibiteurs de l'ido
AU2008353145B2 (en) 2008-01-03 2013-09-12 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
IN2015DN02826A (fr) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (fr) 2009-10-28 2016-10-05 Newlink Genetics Corporation Dérivés imidazole comme inhibiteurs de l'ido
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
NO2694640T3 (fr) 2011-04-15 2018-03-17
CA2833636A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molecules qui se lient a b7-h1 et a pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
RU2015105561A (ru) * 2012-08-09 2016-09-27 Ф. Хоффманн-Ля Рош Аг Замещенные гетероазепиноны
JP6727224B2 (ja) 2015-03-02 2020-07-22 アペイロン・バイオロジックス・アクチェンゲゼルシャフトAPEIRON Biologics AG 新生物疾患および/または感染性疾患の治療にとって有用な二環式テトラヒドロチアゼピン誘導体
MX2023009379A (es) * 2021-02-12 2023-10-10 Hoffmann La Roche Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer.

Also Published As

Publication number Publication date
EP4568958A1 (fr) 2025-06-18
PE20251399A1 (es) 2025-05-22
CR20250042A (es) 2025-03-25
MX2025000918A (es) 2025-03-07
JP2025526727A (ja) 2025-08-15
TW202417438A (zh) 2024-05-01
WO2024033388A1 (fr) 2024-02-15
AU2023322637A1 (en) 2024-11-14
IL318163A (en) 2025-03-01
ZA202408363B (en) 2025-10-29
CO2025001103A2 (es) 2025-02-13
AR130194A1 (es) 2024-11-13
KR20250038674A (ko) 2025-03-19
US20260035364A1 (en) 2026-02-05
CN119698413A (zh) 2025-03-25
CL2025000379A1 (es) 2025-04-11

Similar Documents

Publication Publication Date Title
EP4120820A4 (fr) Dérivés cristallins de psilacétine
EP4038058A4 (fr) Dérivés de cannabinoïdes
EP3911631A4 (fr) Nouveaux dérivés de sulfonylurées substitués
EP4308577C0 (fr) Nouveaux dérivés de thiadiazolopyrimidone
MA56504A (fr) Dérivés de pyridin-3-yle
MA71728A (fr) Dérivés bicycliques de tétrahydrothiazépine
EP4229062A4 (fr) Composés bicycliques
EP4166541A4 (fr) Dérivé de diméthylsulfoximines
EP4502309A4 (fr) Urinoir
JP1749680S (ja) 取付用小便器
EP4361159A4 (fr) Dérivé de borono-phénylalanine
EP4157845C0 (fr) Dérivés de pyrrolo [2,3-d] pyrimidine
ZA202408363B (en) Bicyclic tetrahydrothiazepine derivatives
MA53541A (fr) Dérivés hétéroaryles bicycliques
JP1782794S (ja) 取付用小便器
JP1782795S (ja) 取付用小便器
JP1782718S (ja) 取付用小便器
JP1782793S (ja) 取付用小便器
JP1782796S (ja) 取付用小便器
JP1749678S (ja) 取付用小便器
JP1749682S (ja) 取付用小便器
JP1749677S (ja) 取付用小便器
JP1749653S (ja) 取付用小便器
JP1749652S (ja) 取付用小便器
JP1749679S (ja) 取付用小便器